Gurung, M
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
Serious side effects While the majority of the reported side effects with retatrutide were mild to moderate in severity, clinical trials also recorded a small number of serious adverse events
These medications mimic the GLP-1 hormone, which regulates appetite and insulin secretion, reducing hunger and improving blood sugar control
Set phone reminders if needed
More recently, encouraging clinical results from a triple-hormone-receptor agonist, Retatrutide, and several GLP-1R/GCGR dual agonists, suggest that GCGR could be a promising co-stimulating target for type 2 diabetes and obesity.